Fiche personne


Territoire

Alsace

Statut

Hospitalier

Équipes/plateformes

Oncologie médicale

Projets


Publications


Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial.

Jordan SE, González-Martin A, Morlock R, Hubig L, Yonemori K, Eberst L, Zikan M, Kim HS, Banerjee S, Damian F, Salutari V, Henry S, Raimondo M, Kolinsky M, Woelber L, Tromp J, Hietanen S, Nishio S, Lee JY, Manso L, Cruz F, Barraclough L, Oaknin A, Van Nieuwenhuysen E, Randall L, Lo SH, Mutebi A, Abrahami D, Leary A, Vergote I

Int J Gynecol Cancer. 2026 08 11;:104947

Efficacy and safety of immune checkpoint inhibitor rechallenge in cervical and endometrial cancer: a multi-center retrospective study (RICE study).

Kabirian R, de Saint Ghislain M, Le Saux O, Mathiot L, Frenel JS, Augereau P, Forestier A, Fumet JD, Eberst L, Quesada S, Kalbacher E, Lescure C, De La Motte Rouge T, Grau Bejar JF, Barraud S, Genevee T, Bello Roufai D, Rodrigues M, Leary A

Int J Gynecol Cancer. 2026 07 15;:104867

Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25).

Joly F, Anota A, Chabaud S, Cropet C, Priou F, Harter P, Pignata S, Palacio I, Petru E, Kobayashi H, Vergote I, Parma G, Mäenpää J, Raymond E, Ataseven B, Pisano C, Lainez N, Tsibulak I, Yonemori K, Vuylsteke P, Lapresa MT, Mirza MR, Bouchaert P, Buderath P, Lorusso D, Herrero A, Eberst L, Burges A, Scambia G, Ortega E, Guillemet C, Pujade-Lauraine E, Kurtz JE, Ray-Coquard I

J Natl Cancer Inst. 2026 04 24;:

Voir plus